Mouse Models as a Tool for Understanding Progression in Braf V600E -Driven Thyroid Cancers.

The development of next generation sequencing (NGS) has led to marked advancement of our understanding of genetic events mediating the initiation and progression of thyroid cancers. The NGS studies have confirmed the previously reported high frequency of mutually-exclusive oncogenic alterations affecting BRAF and RAS proto-oncogenes in all stages of thyroid cancer. Initially identified by traditional sequencing approaches, the NGS studies also confirmed the acquisition of alterations that inactivate tumor protein p53 ( TP53 ) and activate phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA ) in advanced thyroid cancers. Novel alterations, such as those in telomerase reverse transcriptase ( TERT ) promoter and mating-type switching/sucrose non-fermenting (SWI/SNF) complex, are also likely to promote progression of the BRAF ^V600E -driven thyroid cancers. A number of genetically engineered mouse models (GEMM) of BRAF ^V600E -driven thyroid cancer have been developed to investigate thyroid tumorigenesis mediated by oncogenic BRAF and to explore the role of genetic alterations identified in the genomic analyses of advanced thyroid cancer to promote tumor progression. This review will discuss the various GEMMs that have been developed to investigate oncogenic BRAF ^V600E -driven thyroid cancers.
Competing Interests: No potential conflict of interest relevant to this article was reported.
(Copyright © 2019 Korean Endocrine Society.)